FOLH1 and neoplasm: Nanoparticles of different formulations, such as liposomes, polymeric nanoparticles, and inorganic nanoparticles, can be designed to encapsulate molecular targeted drugs, and to selectively accumulate in prostate tumors through conjugation with antibodies that specifically recognize tumor-associated markers, such as PSMA, enhancing tumor targeting and internalization.